Tokenwell Platforms Inc., Formerly Trilogy AI Corp., Announces Stock Option Grants

Rhea-AI Summary

Tokenwell Platforms Inc. (TRAIF), formerly known as Trilogy AI Corp., has announced the grant of 2,025,000 stock options to its directors, officers, and consultants. The options are exercisable at $0.35 per share with a three-year expiration period. The vesting schedule is structured as 25% every six months from the award date.

Of the total grant, Mr. Burgess received 1,300,000 stock options. Additionally, the Board has authorized Mr. Burgess to approve up to 1,150,000 additional stock options for future employee and consultant retention purposes.

Positive

• None.

Negative

• Potential dilution from 3,175,000 total stock options if exercised

Vancouver, British Columbia--(Newsfile Corp. - August 12, 2025) - Tokenwell Platforms Inc. (formerly Trilogy AI Corp.) ("Tokenwell" or the "Company") is pleased to announce that it has granted an aggregate of 2,025,000 stock options to directors, officers and consultants of the Company; the stock options are exercisable at a price of $0.35, and shall vest as follows: ¼ to vest every six months beginning on the date that is six months from the award date. The stock options will expire three years from the issue date. This grant includes the award to Mr. Burgess of 1,300,000 stock options upon the aforementioned terms.

Additionally, the Company's Board of Directors has authorized Mr. Burgess to approve the grant of up to an additional 1,150,000 stock options to certain individuals in connection with their retention as employees / consultants of the Company.

About Tokenwell Platforms Inc.

Tokenwell Platforms Inc. is a financial technology company focused on enhancing access to intelligent cryptocurrency investing through its innovative, user-centric platform.

Further Information

For further information, please contact:

Tokenwell Platforms Inc.
Timothy J. Burgess
Chief Executive Officer and Director
Email: info@tokenwell.com

Neither the CSE nor its Regulation Services Provider accepts responsibility for the adequacy or accuracy of this news release. No stock exchange, securities commission or other regulatory authority has approved or disapproved the information contained herein.

Cautionary Note Regarding Forward-Looking Information

This news release contains statements and information that, to the extent that they are not historical fact, may constitute "forward-looking information" within the meaning of applicable securities legislation based on current expectations, estimates, forecasts, projections, beliefs and assumptions made by management of the Company. Forward-looking information is generally identified by words such as "believe", "project", "aim", "expect", "anticipate", "estimate", "intend", "strategy", "future", "opportunity", "plan", "may", "should", "will", "would", and similar expressions and, in this news release, includes statements relating to the commencement of trading of the common shares of the Company, the financial and business prospects of the Company, its assets and other matters. Although the Company believes that the expectations and assumptions on which such forward-looking information are reasonable, undue reliance should not be placed on the forward-looking information because the Company can give no assurance that it will prove to be correct. Since forward-looking information addresses future events and conditions, by its very nature it involves inherent risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking information in this news release. The forward-looking information included in this news release is expressly qualified by this cautionary statement. The forward-looking information contained in this news release is made as of the date hereof and the Company undertakes no obligation to update publicly or revise any forward-looking information, whether as a result of new information, future events or otherwise, unless so required by applicable laws.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/262302

FAQ

How many stock options did Tokenwell Platforms (TRAIF) grant in August 2025?

Tokenwell Platforms granted 2,025,000 stock options to directors, officers, and consultants, with an additional authorization for up to 1,150,000 options.

What is the exercise price for Tokenwell Platforms' (TRAIF) stock options granted in August 2025?

The stock options are exercisable at $0.35 per share.

What is the vesting schedule for Tokenwell Platforms' (TRAIF) August 2025 stock options?

The stock options vest 25% every six months beginning six months from the award date.

How many stock options did Mr. Burgess receive from Tokenwell Platforms (TRAIF)?

Mr. Burgess received 1,300,000 stock options and was authorized to approve up to an additional 1,150,000 options for employees and consultants.

When do the Tokenwell Platforms (TRAIF) August 2025 stock options expire?

The stock options will expire three years from the issue date.